Year 2025 bigsmile
In his COMPUTEX keynote, NVIDIA CEO Jensen Huang unveiled a vision for an AI-powered future, showcasing new platforms and partnerships.
Category: robotics/AI – Page 11
Interpretation, extrapolation and perturbation of single cells
Causal and mechanistic modelling strategies, which aim to infer cause–effect relationships, provide insights into cellular responses to perturbations. The authors review computational approaches that harness machine learning and single-cell data to advance our understanding of cellular heterogeneity and causal mechanisms in biological systems.
The Singularity Countdown: AGI by 2029, Humans Merge with AI, Intelligence 1000x | Ray Kurzweil
Ray Kurzweil predicts humans will merge with artificial intelligence (AI) by 2045, resulting in a 1000x increase in intelligence and marking the beginning of a new era of unprecedented innovation, potentially transforming human life and society ## ## Questions to inspire discussion.
Preparing for AI Timeline.
🤖 Q: When should I expect human-level AI and what defines it? A: Human-level AI arrives by 2029, defined not by passing the Turing test (which only matches an ordinary person), but as AGI requiring expertise in thousands of fields and the ability to combine insights across disciplines.
🧠 Q: When will the singularity occur and what intelligence gain can I expect? A: The singularity happens by 2045 when humanity merges with AI to become 1000x more intelligent, creating a seamless merger where biological and computational thought processes become indistinguishable.
⚡ Q: How much change should I prepare for in the next decade? A: Expect as much change in the next 10 years as occurred in the last 100 years (1925−2025), with AGI and supercomputers by 2035 enabling merging with AI for 1000x intelligence increase.
Career and Economic Adaptation.
Tesla Robotaxis, AGI Myths, and the Real Economics of the Musk Economy
Elon Musk’s ventures, particularly Tesla’s robotaxis and advancements in AI, are poised to revolutionize the economy and society, with significant potential for growth, discovery, and profound implications for the future ##
## Questions to inspire discussion.
Robotaxi Economics & Business Model.
🚖 Q: What determines robotaxi success beyond achieving autonomy? A: Success depends on unit economics, fleet scalability, and supply elasticity during peak demand, not who reaches autonomy first, with the ability to integrate privately owned vehicles into a single economic system being critical.
💰 Q: What margin advantage does Tesla’s robotaxi model have over competitors? A: Tesla projects 35% margins by 2030, significantly higher than Uber’s 7.9% and Waymo’s break-even margins, enabling rapid revenue growth.
📈 Q: What revenue growth is expected for Tesla’s robotaxi business? A: Tesla expects 4.4-5x growth in robotaxi revenue over the next 5 years, potentially greater due to untapped use cases like long road trips.
Two harmful gene variants can restore function when combined, study reveals
Sometimes, in genetics, two wrongs do make a right. A research team has recently shown that two harmful genetic variants, when occurring together in a gene, can restore function—proving a decades-old hypothesis originally proposed by Nobel laureate Francis Crick.
Their study, to be published in the Proceedings of the National Academy of Sciences, not only experimentally validated this theory but also introduced a powerful artificial intelligence (AI)-driven approach to genetic interpretation led by George Mason University researchers.
The project began when Aimée Dudley, a geneticist at the Pacific Northwest Research Institute (PNRI), approached George Mason University Chief AI Officer Amarda Shehu after following her lab’s work on frontier AI models for predicting the functional impact of genetic variation. That conversation sparked a collaboration that married PNRI’s experimental expertise with George Mason’s computational innovation to discover some surprising ways variant combinations can shape human health.
Agenus Closes Strategic Immunotherapeutic Collaboration with Zydus Lifesciences
As part of the collaboration, Agenus has granted Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka, with Agenus eligible to receive royalties on net sales in those territories.
“Closing this collaboration with Zydus strengthens our balance sheet and, critically, secures dedicated U.S. manufacturing capacity at a pivotal moment for Agenus,” continued Armen. “With these foundations in place, our focus in 2026 is disciplined execution—advancing our Phase III program, broadening paid patient access through authorized pathways, and progressing toward regulatory submission supported by one of the most substantial clinical datasets generated in [microsatellite stable] MSS colorectal cancer.”
Following the closing, the Emeryville and Berkeley, CA, biologics manufacturing facilities will be transferred to Zydus and housed under a newly formed subsidiary named Zylidac Bio. Agenus has secured committed manufacturing capacity at these U.S. sites to support BOT+BAL supply needs for its clinical trials, global access programs, and future commercialization.